The pressure to innovate is especially high, with patents for important, best selling biologics drugs on the way to expiry. As blockbuster brands lose exclusivity, makers of originator drugs are vying with companies producing new, cheaper biosimilar alternatives to retain shares of the market.
Efforts to replenish R&D pipelines and develop the next blockbusters have been too slow to keep up with expiry timelines. At the same time, drug development times and the cost of bringing new drugs to market have increased.
New routes to innovation
In this environment, continued re-investment in R&D needs to be accompanied by new pathways to drug discovery.
To stay competitive, pharmaceutical companies are:
- Changing their business models
- Consolidating their companies
- Increasing the number of R&D partnerships and functions.
Download our report ‘Hot topics in pharma’ to learn more about how the pharmaceutical industry is evolving.
